Guillermo Salinas, MD
Cardiovascular Disease · McAllen, TXNPI 1215065529
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (38.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 32.0% of the total. Reporting peaked in 2022 at $8,120 and has fallen 67.4% since, to $2,650 in 2025.
Across 199 payments — averaging $118.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$8K
- Medtronic$4K
- Edwards Lifesciences$4K
- Abbott$3K
- Boston Scientific$2K
- Abiomed$796
- plus $2K from 19 others
Across 10 payments — averaging $3390.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$34K
What the payments were for
- Consulting fees$6,00025%
- Travel & lodging$8,93638%
- Food & beverage$8,60537%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 14 | $7,530 |
| Medtronic(2 entities) | 45 | $3,925 |
| Edwards Lifesciences | 21 | $3,646 |
| Abbott | 47 | $3,151 |
| Boston Scientific | 16 | $2,450 |
| Abiomed | 7 | $796 |
| Heartflow, Inc. | 3 | $274 |
| Shockwave Medical, Inc | 2 | $267 |
| Silk Road Medical, Inc. | 2 | $225 |
| Cardiovascular Systems Inc. | 4 | $183 |
| Corindus Inc. | 1 | $170 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $159 |
| Novartis | 8 | $145 |
| Acist Medical Systems, Inc. | 5 | $120 |
| Novo Nordisk | 1 | $115 |
| Gilead | 5 | $73 |
| Philips North America LLC | 1 | $60 |
| Pfizer | 3 | $48 |
| Bard Peripheral Vascular, Inc. | 1 | $47 |
| Impulse Dynamics (USA) Inc. | 1 | $46 |
| Amgen | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Preventice Services, LLC | 1 | $19 |
| Cardiva Medical, Inc. | 1 | $17 |
| Atricure, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CorPath Imaging System$6,609
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,826
- ClosureFast$2,231
- GENERAL VASCULAR ACCESS$1,709
- AMPLATZER AMULET$1,095
- PERCLOSE PROGLIDE$774
- COREVALVE EVOLUT R$551
- Impella$469
- ENROUTE Transcarotid Neuroprotection System$300
- CorPath GRX$277
- FFRct$266
- General - Interventional Oncology$169
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$160
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$150
- ENROUTE Transcarotid Stent$150
- Confirm Rx$135
- SYMPLICITY G3$134
- JETi Peripheral Catheter$133
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$117
- Wegovy$115
How this compares
$23,540 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 237 | $278,345 |
| XareltoRivaroxaban | 181 | $205,493 |
| EntrestoSacubitril/Valsartan | 127 | $151,352 |
| BrilintaTicagrelor | 77 | $43,894 |
| Ranolazine ErRanolazine | 247 | $32,126 |
| FarxigaDapagliflozin Propanediol | 27 | $23,755 |
| Repatha SyringeEvolocumab | 32 | $20,069 |
| Praluent PenAlirocumab | 27 | $17,289 |
| Repatha SureclickEvolocumab | 19 | $16,546 |
| JardianceEmpagliflozin | 14 | $14,760 |
| VascepaIcosapent Ethyl | 15 | $9,142 |
| Metoprolol Succinate | 490 | $8,612 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 290 | $6,559 |
| Isosorbide Mononitrate | 149 | $6,011 |
| Icosapent Ethyl | 12 | $5,112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $278,345237 claims |
| NovartisEntresto | $145 | $151,352127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in McAllen
- Mahesh ChanglaniMcAllen$95K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.